Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

State of the art: treatment of nonalcoholic steatohepatitis.

Pearlman M, Loomba R.

Curr Opin Gastroenterol. 2014 May;30(3):223-37. doi: 10.1097/MOG.0000000000000060. Review.

PMID:
24717764
2.

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

Corey KE, Rinella ME.

Dig Dis Sci. 2016 May;61(5):1387-97. doi: 10.1007/s10620-016-4083-8. Epub 2016 Mar 4. Review.

3.

Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Takahashi Y, Sugimoto K, Inui H, Fukusato T.

World J Gastroenterol. 2015 Apr 7;21(13):3777-85. doi: 10.3748/wjg.v21.i13.3777. Review.

4.

Nonalcoholic fatty liver disease: new treatments.

Hardy T, Anstee QM, Day CP.

Curr Opin Gastroenterol. 2015 May;31(3):175-83. doi: 10.1097/MOG.0000000000000175. Review.

5.

Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.

Ganesh S, Rustgi VK.

Clin Liver Dis. 2016 May;20(2):351-64. doi: 10.1016/j.cld.2015.10.009. Epub 2016 Feb 19. Review.

PMID:
27063274
6.

Nonalcoholic fatty liver disease: a systematic review.

Rinella ME.

JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370. Review. Erratum in: JAMA. 2015 Oct 13;314(14):1521.

PMID:
26057287
7.

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Lomonaco R, Sunny NE, Bril F, Cusi K.

Drugs. 2013 Jan;73(1):1-14. doi: 10.1007/s40265-012-0004-0. Review.

PMID:
23329465
8.

Current and future pharmacologic treatment of nonalcoholic steatohepatitis.

Banini BA, Sanyal AJ.

Curr Opin Gastroenterol. 2017 May;33(3):134-141. doi: 10.1097/MOG.0000000000000356. Review.

9.

Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.

Başaranoğlu M, Örmeci N.

Turk J Gastroenterol. 2014 Apr;25(2):127-32. doi: 10.5152/tjg.2014.7675. Review.

10.

Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.

Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.

Dig Dis. 2015;33(4):598-607. doi: 10.1159/000375353. Epub 2015 Jul 6. Review.

PMID:
26159280
11.

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.

Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN).

Aliment Pharmacol Ther. 2013 Jul;38(2):134-43. doi: 10.1111/apt.12352. Epub 2013 May 29.

12.

Therapies in non-alcoholic steatohepatitis (NASH).

Oseini AM, Sanyal AJ.

Liver Int. 2017 Jan;37 Suppl 1:97-103. doi: 10.1111/liv.13302. Review.

13.

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T; Japanese Society of Gastroenterology; Japan Society of Hepatology.

J Gastroenterol. 2015 Apr;50(4):364-77. doi: 10.1007/s00535-015-1050-7. Epub 2015 Feb 24.

PMID:
25708290
14.

Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.

Stein LL, Dong MH, Loomba R.

Adv Ther. 2009 Oct;26(10):893-907. doi: 10.1007/s12325-009-0072-z. Epub 2009 Nov 16. Review.

PMID:
19921118
15.

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN.

N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28.

16.

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J; NASH CRN Research Group.

Contemp Clin Trials. 2009 Jan;30(1):88-96. doi: 10.1016/j.cct.2008.09.003. Epub 2008 Sep 10.

17.

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.

Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS.

Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-15.

PMID:
15625656
18.

Pharmacological management of nonalcoholic fatty liver disease.

Barb D, Portillo-Sanchez P, Cusi K.

Metabolism. 2016 Aug;65(8):1183-95. doi: 10.1016/j.metabol.2016.04.004. Epub 2016 May 21. Review.

19.

Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis.

Mahady SE, Wong G, Craig JC, George J.

Hepatology. 2012 Dec;56(6):2172-9. doi: 10.1002/hep.25887.

PMID:
22707355
20.

Vitamin E and nonalcoholic fatty liver disease.

Pacana T, Sanyal AJ.

Curr Opin Clin Nutr Metab Care. 2012 Nov;15(6):641-8. doi: 10.1097/MCO.0b013e328357f747. Review.

Supplemental Content

Support Center